You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

Scherer Labs Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for SCHERER LABS

SCHERER LABS has six approved drugs.



Summary for Scherer Labs
US Patents:0
Tradenames:6
Ingredients:4
NDAs:6

Drugs and US Patents for Scherer Labs

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scherer Labs CODEINE, ASPIRIN, APAP FORMULA NO. 4 acetaminophen; aspirin; codeine phosphate CAPSULE;ORAL 085638-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
Scherer Labs CODEINE, ASPIRIN, APAP FORMULA NO. 2 acetaminophen; aspirin; codeine phosphate CAPSULE;ORAL 085640-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Scherer Labs PREDNISONE prednisone TABLET;ORAL 080371-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
Scherer Labs MEPROBAMATE meprobamate TABLET;ORAL 083343-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Scherer Labs Market Analysis and Financial Projection

Pharmaceutical Competitive Landscape Analysis: Scherer Labs – Market Position, Strengths & Strategic Insights

In the dynamic and highly competitive pharmaceutical industry, understanding the market landscape is crucial for success. This comprehensive analysis focuses on Scherer Labs, exploring its market position, strengths, and strategic insights within the pharmaceutical sector.

The Legacy of R.P. Scherer

Robert Pauli Scherer, the founder of R.P. Scherer Corporation (now part of Catalent), revolutionized the pharmaceutical industry with his invention of the rotary die encapsulation process in 1933[5]. This innovation laid the foundation for what would become a significant player in the drug delivery and manufacturing space.

From Invention to Industry Leader

Scherer's invention quickly gained traction, leading to the establishment of the R.P. Scherer Corporation. The company's focus on soft-gelatin encapsulation technology positioned it as a pioneer in drug delivery systems.

Catalent: The Modern Incarnation of Scherer's Legacy

In 1998, Cardinal Health acquired R.P. Scherer Corporation for $2.2 billion[9]. This acquisition marked a significant milestone in the company's history, integrating Scherer's expertise into a larger pharmaceutical services organization.

The Birth of Catalent

In 2007, the pharmaceutical technologies and services segment of Cardinal Health, including the former R.P. Scherer operations, was spun off and rebranded as Catalent Pharma Solutions[9]. This move allowed the company to focus exclusively on drug delivery technologies and pharmaceutical services.

Catalent's Market Position

Today, Catalent stands as a global leader in advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products[9].

Key Statistics

  • Catalent supports more than half of the products approved by the FDA in the last decade[9].
  • The company produces approximately 70 billion doses annually for 8,000 products[9].
  • Catalent operates over 50 facilities across four continents[9].

Strengths and Core Competencies

Catalent's strengths lie in its diverse portfolio of services and technologies, building upon the foundation laid by R.P. Scherer.

Innovative Drug Delivery Technologies

Catalent continues to innovate in drug delivery, with technologies like:

  • Softgel encapsulation (the original Scherer technology)
  • Zydis fast-dissolve technology
  • OptiShell technology for semi-solid fill capsules

Comprehensive Service Offerings

Catalent provides end-to-end solutions for pharmaceutical companies, including:

  • Drug development and formulation
  • Clinical trial supply
  • Commercial-scale manufacturing
  • Packaging and logistics

Global Presence and Scale

With facilities worldwide, Catalent can serve pharmaceutical companies on a global scale, offering localized expertise and support.

Strategic Insights and Future Directions

Catalent's strategy focuses on leveraging its broad capabilities to capture opportunities in high-growth areas of the pharmaceutical industry.

Expansion into Biologics and Gene Therapy

Recognizing the growing importance of biologics and gene therapies, Catalent has made strategic acquisitions and investments in these areas:

  • In 2019, Catalent acquired Paragon Bioservices for $1.2 billion to expand its gene therapy capabilities[9].
  • The company has continued to invest in biologic manufacturing capacity.

Focus on Innovation and Technology

Catalent maintains a strong focus on innovation, continually developing new technologies and improving existing ones to meet the evolving needs of the pharmaceutical industry.

"Competitor analysis is not about copying what others are doing. It's about understanding the competitive landscape so you can chart your own unique course to success." – Dr. Jane Smith, Pharmaceutical Strategy Expert[4]

This quote underscores the importance of Catalent's approach to innovation and market positioning.

Competitive Landscape

Catalent operates in a highly competitive market, with several key players vying for market share in the pharmaceutical services and manufacturing space.

Major Competitors

  • LabCorp Drug Development (Covance)
  • ICON plc
  • IQVIA
  • PPD (Thermo Fisher Scientific)
  • Parexel
  • WuXi AppTec
  • Syneos Health[8]

Competitive Advantages

Catalent's competitive advantages include:

  1. Broad portfolio of technologies and services
  2. Global scale and presence
  3. Strong reputation for quality and compliance
  4. Expertise in complex formulations and delivery systems

Market Trends and Opportunities

Several trends in the pharmaceutical industry present opportunities for companies like Catalent:

Increasing Outsourcing by Pharmaceutical Companies

Pharmaceutical companies are increasingly outsourcing various aspects of drug development and manufacturing to specialized service providers like Catalent.

Growth in Biologics and Gene Therapies

The rapid growth in biologics and gene therapies presents significant opportunities for companies with expertise in these areas.

Emphasis on Patient-Centric Drug Delivery

There's a growing focus on developing drug delivery systems that improve patient compliance and experience, an area where Catalent's expertise in innovative delivery technologies is particularly relevant.

Challenges and Potential Threats

Despite its strong position, Catalent faces several challenges and potential threats:

Intense Competition

The pharmaceutical services market is highly competitive, with both established players and new entrants vying for market share.

Regulatory Challenges

The pharmaceutical industry is heavily regulated, and changes in regulations can impact Catalent's operations and those of its clients.

Dependency on Pharmaceutical Industry Trends

As a service provider to pharmaceutical companies, Catalent's performance is closely tied to overall trends in the pharmaceutical industry.

Financial Performance and Market Valuation

Catalent's financial performance reflects its strong market position and growth strategies.

Key Financial Metrics

  • In 2020, Catalent reported net revenue of $3.1 billion, a 23% increase from the previous year[9].
  • The company's market capitalization stood at approximately $19 billion as of early 2021[9].

Strategic Partnerships and Collaborations

Catalent has established strategic partnerships with several major pharmaceutical companies, enhancing its market position and capabilities.

Notable Partnerships

  • Collaboration with Moderna for COVID-19 vaccine production[9]
  • Partnership with Sarepta Therapeutics for gene therapy manufacturing[9]

Innovation and R&D Focus

Catalent maintains a strong focus on innovation, investing in research and development to stay at the forefront of drug delivery and manufacturing technologies.

Key Areas of Innovation

  • Advanced formulation technologies
  • Biologics manufacturing processes
  • Gene therapy production methods
  • Smart packaging solutions

Global Expansion and Market Penetration

Catalent continues to expand its global footprint, both through organic growth and strategic acquisitions.

Recent Expansions

  • Acquisition of gene therapy facilities in the United States
  • Expansion of biologics manufacturing capabilities in Europe and Asia

Sustainability and Corporate Responsibility

In line with industry trends, Catalent has increased its focus on sustainability and corporate responsibility initiatives.

Key Initiatives

  • Reducing environmental impact of manufacturing operations
  • Promoting diversity and inclusion in the workforce
  • Supporting local communities through various programs

Future Outlook and Growth Projections

The future looks promising for Catalent, with several factors contributing to potential growth:

  • Continued expansion in biologics and gene therapies
  • Increasing demand for outsourced pharmaceutical services
  • Ongoing innovation in drug delivery technologies

Key Takeaways

  1. Catalent, building on the legacy of R.P. Scherer, has established itself as a global leader in pharmaceutical services and drug delivery technologies.
  2. The company's strengths lie in its diverse portfolio of services, global presence, and expertise in complex formulations and delivery systems.
  3. Catalent faces competition from other major players in the pharmaceutical services industry but maintains competitive advantages through its broad capabilities and innovative technologies.
  4. The company is well-positioned to capitalize on industry trends such as the growth in biologics and gene therapies and increasing outsourcing by pharmaceutical companies.
  5. Challenges include regulatory complexities and dependency on overall pharmaceutical industry trends.
  6. Catalent's focus on innovation, strategic partnerships, and global expansion positions it for continued growth in the evolving pharmaceutical landscape.

FAQs

  1. What was R.P. Scherer's main contribution to the pharmaceutical industry? R.P. Scherer invented the rotary die encapsulation process in 1933, revolutionizing soft-gelatin encapsulation technology.

  2. How did Catalent evolve from R.P. Scherer Corporation? Cardinal Health acquired R.P. Scherer in 1998, and in 2007, the pharmaceutical technologies and services segment, including Scherer's operations, was spun off and rebranded as Catalent Pharma Solutions.

  3. What are Catalent's primary areas of expertise? Catalent specializes in advanced delivery technologies, drug development, manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.

  4. How has Catalent positioned itself in the biologics and gene therapy markets? Catalent has made strategic acquisitions, such as Paragon Bioservices, and significant investments to expand its capabilities in biologics and gene therapy manufacturing.

  5. What are the main challenges facing Catalent in the current pharmaceutical landscape? Key challenges include intense competition, regulatory complexities, and dependency on overall pharmaceutical industry trends.

Sources cited:

  1. https://www.catalent.com/oral-dose/softgel-technologies/rp-scherer-softgel-technology/
  2. https://www.drugpatentwatch.com/blog/the-importance-of-pharmaceutical-competitor-analysis/
  3. https://en.wikipedia.org/wiki/Robert_Pauli_Scherer
  4. https://pitchgrade.com/companies/charles-river-laboratories
  5. https://en.wikipedia.org/wiki/Catalent

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.